ArticleBioMed research international2017
Serum Butyrylcholinesterase Activity: A Biomarker for Parkinson's Disease and Related Dementia.
Article in BioMed research international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Potential protein blood-based biomarkers for cognitive dysfunction in Parkinson's disease: a systematic review and network meta-analysis.Frontiers in aging neuroscience · 2026Pooled it
- Lower Blood Lipid Level Is Associated with the Occurrence of Parkinson's Disease: A Meta-Analysis and Systematic Review.International journal of clinical practice · 2022Pooled it
- Dopaminergic System Alteration in Anxiety and Compulsive Disorders: A Systematic Review of Neuroimaging Studies.Frontiers in neuroscience · 2020Pooled it
- Molecular Mechanisms and Network Pharmacology Revealing Therapeutic Potential of Acetamidosulfonamides against Parkinsonian Model.ACS omega · 2026Article
- Systematic discovery of disease-modifying targets by prediction from knowledge graph-based AI model and experimental validation: Parkinson's disease case.Computational and structural biotechnology journal · 2026Article
- Serum butyrylcholinesterase activity as a predictor of severity and mortality in COVID-19 patients.Scientific reports · 2025Article
- Plasma proteomics identify biomarkers predicting Parkinson's disease up to 7 years before symptom onset.Nature communications · 2024Article
- First report on the toxicity of SARS-CoV-2, alone and in combination with polyethylene microplastics in neotropical fish.The Science of the total environment · 2023Article
- Liquid chromatography-mass spectrometry-based metabolomic profiling reveals sex differences of lipid metabolism among the elderly from Southwest China.BMC geriatrics · 2023Article
- Fluorescent cyclopropyl ester probes are efficiently cleaved by endogenous carboxylesterase in mouse blood: implications for preclinical fluorescence imaging.Supramolecular chemistry · 2023Article
- Association between cholinesterase activity and critical illness brain dysfunction.Critical care (London, England) · 2022Article
- Mulberry leaves juice attenuates arsenic-induced neurobehavioral and hepatic disorders in mice.Food science & nutrition · 2022Article
- Parental Lead Exposure Promotes Neurobehavioral Disorders and Hepatic Dysfunction in Mouse Offspring.Biological trace element research · 2022Article
- Cholinergic Modulation of the Immune System in Neuroinflammatory Diseases.Diseases (Basel, Switzerland) · 2021Review
- Lipid metabolic dysregulation is involved in Parkinson's disease dementia.Metabolic brain disease · 2021Article
- Salivary biomarkers in Alzheimer's disease.Clinical oral investigations · 2020Article
- Possible Correlation between Cholinergic System Alterations and Neuro/Inflammation in Multiple Sclerosis.Biomedicines · 2020Review
- Understanding the enzyme-ligand complex: insights from all-atom simulations of butyrylcholinesterase inhibition.Journal of biomolecular structure & dynamics · 2020Article
- Integrated Metabolomics and Proteomics Analysis Reveals Plasma Lipid Metabolic Disturbance in Patients With Parkinson's Disease.Frontiers in molecular neuroscience · 2020Article
- Serum Level and Activity of Butylcholinesterase: A Biomarker for Post-Stroke Dementia.Journal of clinical medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aim to determine changes of serum butyrylcholinesterase (BChE) activity in PD patients and related dementia. PATIENTS AND
methodsConsecutive PD patients and healthy controls were included and clinical data were collected. Fast serum BChE activity was determined and compared between healthy controls and PD patients. Independent risk factors were performed for BChE activity, PD, and related dementia. The relationship between BChE activity and disease severity was also evaluated. Receiver operating characteristic (ROC) curves were obtained to explore serum BChE activity in distinguishing PD patients and related dementia.
resultsSerum BChE activity mainly independently correlated with gender, albumin, triglyceride, body mass index, and PD. Serum BChE activity decreased in PD patients compared with healthy controls. Based on the ROC curve, the optimal cut-off point was 6864.08 IU/L for distinguishing PD patients, and the sensitivity and specificity values were 61.8% and 72.1%. It inversely correlated with Unified Parkinson's Disease Rating Scale score. BChE activity decreased in PD-related dementia compared with those without dementia. The sensitivity and specificity values were 70.6% and 76.3%, respectively, with an optimal cut-off point of 6550.00 IU/L.
conclusionsSerum BChE activity can be regarded as a biomarker for PD and related dementia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.